Global

January 13, 2010.

Dr Kay Wardle of RSA examines the impact of short-term survival strategies on pre-clinical R&D organizations.

January 06, 2010.

January 04. 2010.

Quintiles' Jim Featherstone asks what the end of the blockbuster generation means for the sales operation?s business model and how pharma should react to the transition.

David Sun of InterbrandHealth looks at global pharma branding trends for 2010 and beyond.

Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal

With a weak pound being outpaced by the euro, many hospitals are sending drugs to the Continent for higher profits. What can NHS do to stop this practice?

06 August 2009

18 August 2009

11 August

3 August 2009

31 July 2009

Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.

16 July 2009

08 July 2009

UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.

Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.

12 June 2009

9 June 2009

A 45-minute webinar on assay and system validation hosted by Marian Kelley, contributing author of DeSilva white paper, on behalf of Gyros AB.

New prediction reflects incremental pressure from economic crisis.

4 June 2009

1 June 2009

1 June 2009

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems.

It could be the end of the road for the UK's biotech firms if drastic action isn't taken soon.

EC proposal loosens restrictions on drug packaging and information dissemination.

In Europe, it's different strokes for different folks at the top regulatory agencies